Study of the Reunion BRCA2 Mutation in Breast Cancer Patients Evaluating Genetic Factors and Mutation Prevalence in Breast Cancer in Reunion

What this Trial Is About

Breast cancer is the most common cancer among women in mainland France and Reunion, responsible for significant mortality despite generally having a good prognosis. This research focuses on the genetic aspects of breast cancer in Reunion, particularly the prevalence of a specific BRCA2 gene mutation found in the local population. Understanding this mutation could help adapt genetic consultations and preventive measures for breast cancer in the region. Participants in this study will provide a blood sample to detect the Reunion-specific BRCA2 mutation c.2612C>A mutation of exon 11. The study is interventional and aims to determine how common this mutation is among breast cancer patients in Reunion. Only patients diagnosed with a first or second breast cancer during the inclusion period and living in Reunion are eligible. Participants will be assessed at the time of inclusion through genetic testing of the blood sample. The main outcome measured is the prevalence of the Reunion BRCA2 mutation in individuals diagnosed with breast cancer. The study does not involve masking or placebo groups. Participation involves consenting to genetic testing and sharing relevant health information, with no long-term treatment or follow-up detailed.

Contribution of Oncogenetics in Breast Cancer in Reunion Epidemiology of Breast Cancer in Reunion: Study of the Reunion Mutation on BRCA2